TORONTO, June 19, 2026, 15:06 (EDT)
- WELL Health slipped 3.7% to C$4.19 in Toronto’s delayed market as of 2:48 p.m. EDT, trailing a mostly unchanged S&P/TSX Composite.
- Canadian exchanges stayed open during Juneteenth. U.S. exchanges closed, so WELL traded on a lighter North American tape.
- WELL Health Technologies posted its director vote results, but traders are still looking at Circle Medical, Q1 cash conversion, and what the clinic-and-software platform is worth.
WELL Health Technologies Corp. dropped late Friday in Toronto, trailing the Canadian market. Investors set aside governance updates and kept focus on whether the health clinic group will turn strong revenue gains into better cash flow.
The stock moved during a regular day for Canadian trading, with U.S. markets closed for Juneteenth. Earlier, Canada’s main stock index stayed mostly flat, Reuters said, as gains in energy shares balanced out declines from gold miners.
WELL put out a release, but it wasn’t about earnings. The company said shareholders approved all director nominees at the AGM. 90.7 million shares, or 35.5% of the outstanding, were voted by proxy, WELL said.
Circle Medical is the bigger challenge for WELL. The company, which owns most of the U.S. telehealth platform, said last week it settled a U.S. Attorney’s Office probe into old billing and supervision issues. WELL paid US$3.3 million, matching earlier guidance, and did not admit any wrongdoing. Darren Binder, who runs legal and risk at Circle Medical, said the company “collaboratively resolved this matter.” Circle Medical CEO Georgia Psarras said compliance moves have left the unit “better positioned to scale responsibly.” WELL Health Technologies
Bulls are still in the picture. Stifel analyst Justin Keywood stuck with a C$8.25 price target on WELL after the Circle Medical news, according to Cantech Letter on Wednesday, putting the focus back on the gap with the actual stock price and what some sell-siders see as fair value.
The market didn’t show much confidence in WELL on Friday. Trading suggested investors are still waiting to see smoother cash flow, with board decisions and expansion—new clinics, more software, more patients—not moving the needle unless the numbers change.
WELL posted Q1 revenue of C$368.3 million in May, up 25% from last year. Adjusted EBITDA came in at C$43.1 million, up 56%. The company defines adjusted EBITDA as earnings before interest, tax, depreciation and amortization, with further adjustments for what it calls non-recurring items. WELL says this figure is not an IFRS accounting metric and may not be directly comparable with peers.
WELL CEO Hamed Shahbazi said at the time the company’s revenue run rate was closing in on “the $1.5 billion per year mark,” with Canadian clinics giving a boost. CFO Eva Fong said Q2 should be the last quarter of Circle Medical deferrals, which are related to how the company recognizes some revenue as opposed to when cash actually comes in. WELL Health Technologies
Competition around WELL is squeezed but patchy. Investors looking for a public-market play on Canada’s clinic-rollup and EMR angle have few pure options—WELL is one. Electronic medical records, or EMR, are the software tools doctors use for storing patient charts. Main rivals include Telus Health and QHR, which sits under Loblaw. Each is part of a much bigger group.
But there’s a problem for WELL. Operating adjusted free cash flow attributable to shareholders dropped to C$1.6 million in Q1, down from C$11.8 million a year ago. WELL said the fall was due to clinic investments, more cash taxes, delayed Circle Medical revenue, and higher interest after taking bigger credit. If revenue gains slow, or Circle Medical margins don’t pick up after Q2 as expected, Friday’s stock discount might stick around longer than bulls hope.
